Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy.
Lohrmann E, Jaeger T, Enekebe K, Zhang Z, Wilt T, Riggen M, Stemhagen A, Nair I, Nunna S, Fernandes AW, Gandhi H, Sergeyeva O, George V.
Lohrmann E, et al. Among authors: nair i.
Clin Kidney J. 2025 Feb 25;18(3):sfaf062. doi: 10.1093/ckj/sfaf062. eCollection 2025 Mar.
Clin Kidney J. 2025.
PMID: 40130227
Free PMC article.